| Antibiotic Used Parameter | Antibiotics Treated | No-Antibiotics |
| Number of patients | 87 (70.16%) | 37 (29.84%) |
| Death | 71 (57.26%) | 27 (21.77%) |
| ALOS | 14.32 day | 9.47 day |
| Single antibiotics: | 30 (34.09%) |
|
| Levofloxacin | 18 (20.45%) Died14 (77.77%) |
|
| Cefoperazone Sulbactam | 9 (10.23%) Died 5 (55.55%) |
|
| Cefotaxime | 1 |
|
| Meropenem | 1 |
|
| Ceftazidime | 1 |
|
| Levofloxacin induces subsequent use of antibiotic | 24 (27.27%) Died 23 (95.83%) |
|
| Quantitative Analysis: |
|
|
| Meropenem | 17.70 DDD |
|
| Cefo-Sulbactam | 16.87DDD |
|
| Ceftazidime | 6.64 DDD |
|
| Cefotaxime | 0.41 DDD |
|
| Ampi-Sulbactam | 2.07 DDD |
|
| Levofloxacin | 46.16 DDD |
|
| Moxifloxacin | 1.58 DDD |
|
| Amikacin | 5.56 DDD |
|
| Gentamicin | 1.4 DDD |
|
| Fluconazole | 7.43 DDD |
|
| Metronidazole | 1.09 DDD |
|
| Vancomycin | 0.97 DDD |
|
| Qualitative Analysis: |
|
|
| Category 0 | 81 (43.55%) |
|
| Category I | 0 |
|
| Category II | 0 |
|
| Category IIIA | 2 (1.10%) |
|
| Category IIIB | 5 (2.69%) |
|
| Category IVA | 44 (23.65%) |
|
| Category V | 53 (28.49%) |
|
| Category VI | 1 (0.54%) |
|